Table of Contents Author Guidelines Submit a Manuscript
Spectroscopy: An International Journal
Volume 27, Article ID 502497, 6 pages
http://dx.doi.org/10.1155/2012/502497

The V30M Amyloidogenic Mutation Decreases the Rate of Refolding Kinetics of the Tetrameric Protein Transthyretin

1Department of Chemistry, Faculty of Science and Technology, University of Coimbra, 3004-535 Coimbra, Portugal
2Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
3Institute of Molecular and Cell Biology (IBMC), University of Porto, 4150-1801 Porto, Portugal

Copyright © 2012 Catarina S. H. Jesus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Ohnishi and K. Takano, “Amyloid fibrils from the viewpoint of protein folding,” Cellular and Molecular Life Sciences, vol. 61, no. 5, pp. 511–524, 2004. View at Publisher · View at Google Scholar
  2. R. M. M. Brito, A. M. Damas, and M. J. M Saraiva, “Amyloid formation by transthyretin: from protein stability to protein aggregation,” Current Medicinal Chemistry—Immunology, Endocrine & Metabolic Agents, vol. 3, no. 4, pp. 349–360, 2003. View at Google Scholar
  3. D. R. Soprano, J. Herbert, K. J. Soprano, E. A. Schon, and D. S Goodman, “Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat,” The Journal of Biological Chemistry, vol. 260, no. 21, pp. 11793–11798, 1985. View at Google Scholar · View at Scopus
  4. G. T. Vatassery, H. T. Quach, W. E. Smith, B. A. Benson, and J. H. Eckfeldt, “A sensitive assay of transthyretin (prealbumin) in human cerebrospinal fluid in nanogram amounts by ELISA,” Clinica Chimica Acta, vol. 197, no. 1, pp. 19–25, 1991. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Hamilton, L. K. Steinrauf, B. C. Braden et al., “The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30→Met variant to 1.7-Å resolution,” The Journal of Biological Chemistry, vol. 268, no. 4, pp. 2416–2424, 1993. View at Google Scholar · View at Scopus
  6. C. J. Terry, A. M. Damas, P. Oliveira et al., “Structure of Met30 variant of transthyretin and its amyloidogenic implications,” The EMBO Journal, vol. 12, no. 2, pp. 735–741, 1993. View at Google Scholar · View at Scopus
  7. V. L. Shnyrov, E. Villar, G. G. Zhadan et al., “Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin,” Biophysical Chemistry, vol. 88, no. 1–3, pp. 61–67, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Hammarström, X. Jiang, A. R. Hurshman, E. T. Powers, and J. W. Kelly, “Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, supplement 4, pp. 16427–16432, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. R. H. Babbes, E. T. Powers, and J. W. Kelly, “Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis,” Biochemistry, vol. 47, no. 26, pp. 6969–6984, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Quintas, M. J. M. Saraiva, and R. M. M. Brito, “The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis,” The Journal of Biological Chemistry, vol. 274, no. 46, pp. 32943–32949, 1999. View at Publisher · View at Google Scholar
  11. A. Quintas, D. C. Vaz, I. Cardoso, M. J. M. Saraiva, and R. M. M. Brito, “Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants,” The Journal of Biological Chemistry, vol. 276, no. 29, pp. 27207–27213, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Furuya, M. J. Saraiva, M. A. Gawinowicz et al., “Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP),” Biochemistry, vol. 30, no. 9, pp. 2415–2421, 1991. View at Publisher · View at Google Scholar
  13. M. R. Almeida, A. M. Damas, M. C. Lans, A. Brouwer, and M. J. M Saraiva, “Thyroxine binding to transthyretin Met 119: comparative studies of different heterozygotic carriers and structural analysis,” Endocrine, vol. 6, no. 3, pp. 309–315, 1997. View at Google Scholar · View at Scopus
  14. A. Raz and D. S. Goodman, “The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex,” The Journal of Biological Chemistry, vol. 244, pp. 3230–3237, 1969. View at Google Scholar
  15. P. Hammarström, X. Jiang, S. Deechongkit, and J. W. Kelly, “Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy,” Biochemistry, vol. 40, no. 38, pp. 11453–11459, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. R. L. Wiseman, E. T. Powers, and J. W. Kelly, “Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease,” Biochemistry, vol. 44, no. 50, pp. 16612–16623, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. E. T. Powers and D. L. Powers, “A perspective on mechanisms of protein tetramer formation,” Biophysical Journal, vol. 85, no. 6, pp. 3587–3599, 2003. View at Google Scholar · View at Scopus